BC
LVTX

Bruce & Co’s LAVA Therapeutics LVTX Stock Holding History

Bruce & Co’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-521,874
Closed -$689K – 40
2025
Q2 		$689K Hold
521,874
– – 0.22% 35
2025
Q1 		$663K Sell
521,874
-250,000
-32% -$278K 0.21% 35
2024
Q4 		$733K Hold
771,874
– – 0.24% 33
2024
Q3 		$1.28M Hold
771,874
– – 0.37% 31
2024
Q2 		$1.39M Hold
771,874
– – 0.46% 28
2024
Q1 		$2.57M Hold
771,874
– – 0.85% 23
2023
Q4 		$1.22M Hold
771,874
– – 0.43% 27
2023
Q3 		$1.15M Hold
771,874
– – 0.39% 27
2023
Q2 		$1.57M Buy
771,874
+100,000
+15% +$185K 0.44% 26
2023
Q1 		$1.12M Buy
671,874
+571,874
+572% +$1.6M 0.3% 28
2022
Q4 		$350K Buy
+100,000
New +$459K 0.09% 34

Other funds holding LVTX

SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Bruce & Co's LVTX Position: Q3 2025 in Review

Bruce & Co sold out of LAVA Therapeutics (LVTX) in Q3 2025, closing a stake of 521,874 shares — an estimated $689K sold.

Bruce & Co first reported a position in LVTX in Q4 2022 and held it in 11 quarters. The position peaked at $2.57M in Q1 2024. 21 funds tracked by Wall St. Rank hold LVTX as of Q3 2025.

  • Bruce & Co reported no remaining LAVA Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bruce & Co sold 521,874 LAVA Therapeutics shares in Q3 2025, an estimated $689K.
  • Bruce & Co first reported a position in LAVA Therapeutics in Q4 2022 and held it in 11 quarters.
  • Bruce & Co's LAVA Therapeutics position peaked at $2.57M in Q1 2024.
  • 21 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q3 2025.

Based on Bruce & Co's 13F filing for Q3 2025, filed 13 Nov 2025.